Tazeen Ahmad
Stock Analyst at B of A Securities
(2.46)
# 2,335
Out of 4,884 analysts
206
Total ratings
46.15%
Success rate
-0.98%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCRX BioCryst Pharmaceuticals | Maintains: Buy | $13 → $15 | $8.94 | +67.79% | 12 | Jul 1, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Neutral | $76 → $28 | $18.24 | +53.51% | 22 | Jun 16, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $201 → $216 | $174.18 | +24.01% | 10 | Jun 9, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $18 → $23 | $20.95 | +9.79% | 14 | Jun 5, 2025 | |
| PRTA Prothena Corporation | Downgrades: Underperform | $22 → $4 | $6.44 | -37.84% | 6 | May 28, 2025 | |
| STRO Sutro Biopharma | Maintains: Underperform | $1 → $0.8 | $0.76 | +4.82% | 3 | May 19, 2025 | |
| DNLI Denali Therapeutics | Maintains: Buy | $28 → $27 | $14.69 | +83.80% | 3 | May 19, 2025 | |
| APLS Apellis Pharmaceuticals | Downgrades: Neutral | $41 → $23 | $18.26 | +25.96% | 7 | May 9, 2025 | |
| PTCT PTC Therapeutics | Upgrades: Buy | $55 → $68 | $49.07 | +38.58% | 17 | May 9, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $63 → $68 | $65.77 | +3.39% | 8 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $302 → $325 | $331.91 | -2.08% | 3 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $28 | $7.95 | +252.20% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $70 | $53.82 | +30.06% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $40 | $4.24 | +843.40% | 4 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $184 → $179 | $129.11 | +38.64% | 3 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $11.98 | +83.64% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $3 | $1.22 | +145.90% | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $68 → $90 | $68.45 | +31.48% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $6.10 | +145.90% | 5 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $11 → $6 | $9.20 | -34.78% | 14 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $150 | $110.00 | +36.36% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $10 → $2 | $6.92 | -71.10% | 6 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $535 → $607 | $543.48 | +11.69% | 3 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $83 → $76 | $39.91 | +90.43% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $2.89 | +246.02% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $1.12 | +435.71% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $9.62 | +55.93% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $8 → $11 | $18.60 | -40.86% | 3 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $2.85 | -29.82% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $0.79 | +655.76% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $8.36 | +79.43% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $47.26 | +26.96% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $1.10 | +1,354.55% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $43 | $10.16 | +323.23% | 2 | Sep 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $175.98 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $11.60 | +2,486.21% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $2.91 | +209.28% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $23.22 | +106.72% | 6 | Oct 10, 2018 |
BioCryst Pharmaceuticals
Jul 1, 2025
Maintains: Buy
Price Target: $13 → $15
Current: $8.94
Upside: +67.79%
Sarepta Therapeutics
Jun 16, 2025
Downgrades: Neutral
Price Target: $76 → $28
Current: $18.24
Upside: +53.51%
Ascendis Pharma
Jun 9, 2025
Maintains: Buy
Price Target: $201 → $216
Current: $174.18
Upside: +24.01%
ACADIA Pharmaceuticals
Jun 5, 2025
Maintains: Neutral
Price Target: $18 → $23
Current: $20.95
Upside: +9.79%
Prothena Corporation
May 28, 2025
Downgrades: Underperform
Price Target: $22 → $4
Current: $6.44
Upside: -37.84%
Sutro Biopharma
May 19, 2025
Maintains: Underperform
Price Target: $1 → $0.8
Current: $0.76
Upside: +4.82%
Denali Therapeutics
May 19, 2025
Maintains: Buy
Price Target: $28 → $27
Current: $14.69
Upside: +83.80%
Apellis Pharmaceuticals
May 9, 2025
Downgrades: Neutral
Price Target: $41 → $23
Current: $18.26
Upside: +25.96%
PTC Therapeutics
May 9, 2025
Upgrades: Buy
Price Target: $55 → $68
Current: $49.07
Upside: +38.58%
Rhythm Pharmaceuticals
Apr 10, 2025
Maintains: Buy
Price Target: $63 → $68
Current: $65.77
Upside: +3.39%
Mar 21, 2025
Maintains: Buy
Price Target: $302 → $325
Current: $331.91
Upside: -2.08%
Mar 12, 2025
Maintains: Buy
Price Target: $54 → $28
Current: $7.95
Upside: +252.20%
Mar 10, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $53.82
Upside: +30.06%
Mar 10, 2025
Maintains: Buy
Price Target: $42 → $40
Current: $4.24
Upside: +843.40%
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $129.11
Upside: +38.64%
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $11.98
Upside: +83.64%
Dec 16, 2024
Downgrades: Underperform
Price Target: $6 → $3
Current: $1.22
Upside: +145.90%
Oct 30, 2024
Upgrades: Buy
Price Target: $68 → $90
Current: $68.45
Upside: +31.48%
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $6.10
Upside: +145.90%
Oct 9, 2024
Maintains: Underperform
Price Target: $11 → $6
Current: $9.20
Upside: -34.78%
Sep 16, 2024
Maintains: Buy
Price Target: $125 → $150
Current: $110.00
Upside: +36.36%
Sep 12, 2024
Downgrades: Underperform
Price Target: $10 → $2
Current: $6.92
Upside: -71.10%
Jun 24, 2024
Reiterates: Buy
Price Target: $535 → $607
Current: $543.48
Upside: +11.69%
May 31, 2024
Maintains: Buy
Price Target: $83 → $76
Current: $39.91
Upside: +90.43%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $2.89
Upside: +246.02%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $1.12
Upside: +435.71%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $9.62
Upside: +55.93%
Dec 7, 2023
Maintains: Underperform
Price Target: $8 → $11
Current: $18.60
Upside: -40.86%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $2.85
Upside: -29.82%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $0.79
Upside: +655.76%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $8.36
Upside: +79.43%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $47.26
Upside: +26.96%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $1.10
Upside: +1,354.55%
Sep 25, 2020
Upgrades: Buy
Price Target: $43
Current: $10.16
Upside: +323.23%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $175.98
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $11.60
Upside: +2,486.21%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $2.91
Upside: +209.28%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $23.22
Upside: +106.72%